Aclaris Therapeutics (ACRS) Cash from Investing Activities (2014 - 2026)

Aclaris Therapeutics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$30.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 261.79% year-over-year to -$30.9 million; the TTM figure through Mar 2026 stood at -$1.7 million (up 97.5% YoY), while the FY2025 annual figure was $48.4 million, up 169.32% from the prior year.
• Cash from Investing Activities was -$30.9 million for Q1 2026 at Aclaris Therapeutics, down from $10.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $32.5 million in Q3 2023 to a low of -$88.7 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged $383058.8 across 5 years, with a median of $5.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 2573.29% in 2023, then plunged 1275.14% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $2.7 million in 2022, then soared by 179.42% to $7.6 million in 2023, then slumped by 1275.14% to -$88.7 million in 2024, then jumped by 111.69% to $10.4 million in 2025, then tumbled by 398.31% to -$30.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$30.9 million (Q1 2026), $10.4 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.